Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada ; Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
Onco Targets Ther. 2013;6:107-18. doi: 10.2147/OTT.S30238. Epub 2013 Feb 26.
To review the available systemic treatments for women with recurrent ovarian cancer.
A literature review was conducted for recurrent ovarian cancer articles in English, including randomized trials, Phase II trials, or reviews.
We discuss the efficacy and toxicity outcomes associated with systemic therapy for platinum-sensitive and platinum-resistant ovarian cancer. Clearly, platinum-based combination systemic therapy shows a prolonged progression-free interval compared with single-agent chemotherapy with a low toxicity profile. No clear superior management strategy exists for platinum-resistant/refractory disease. Novel targeted antiangiogenic agents (eg, bevacizumab), angiopoeitin inhibitors (eg, AMG 386), and poly ADP ribose polymerase inhibitors (eg, olaparib) are reviewed.
Although combination platinum-based chemotherapy has shown benefits for women with platinum-sensitive recurrent ovarian cancer, the optimal treatment strategy for those with platinum-resistant or platinum-refractory disease is not clear. Molecular and genetic targeted therapies may provide opportunities for those women with tumor profiles that show sensitivity for specific agents.
综述女性复发性卵巢癌的现有全身治疗方法。
对英文复发性卵巢癌相关文献进行了综述，包括随机试验、Ⅱ期试验或综述。
我们讨论了与铂敏感和铂耐药卵巢癌全身治疗相关的疗效和毒性结果。显然，与低毒性单药化疗相比，铂类联合全身化疗显示出更长的无进展间期。对于铂耐药/难治性疾病，尚无明确的优势管理策略。新型靶向抗血管生成药物（如贝伐珠单抗）、血管生成素抑制剂（如 AMG 386）和多聚 ADP 核糖聚合酶抑制剂（如奥拉帕尼）也进行了综述。
虽然含铂化疗方案对铂敏感复发性卵巢癌患者有益，但铂耐药或铂难治性疾病患者的最佳治疗策略尚不清楚。分子和基因靶向治疗可能为那些肿瘤特征显示对特定药物敏感的患者提供机会。
